U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07497607) titled 'Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma' on March 23.
Brief Summary: This is a single-arm, phase II study that is designed to investigate nodal and primary tumor CTV dose de-escalation (30 Gy) in HPV positive oropharyngeal cancer.
Study Start Date: June 01, 2026
Study Type: INTERVENTIONAL
Condition:
Oropharyngeal Squamous Cell Carcinoma
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Intervention:
DRUG: Cisplatin
Subjects will continue to receive standard systemic therapy of cisplatin during radiation therapy. Weekly SOC Cisplatin at a dose of 40mg/m2 or every 3-week dosing of 10...